Year: 2021

We are pleased to announce an update to our Schizophrenia treatment algorithm. All TreatGx users now have access to the updated algorithm which includes many exciting enhancements that will help health care providers select the safest and most effective medications for…

All TreatGx users now have access to the updated treatment algorithm for Chronic Pain – Fibromyalgia. This update incorporates information from the most recent clinical guidelines and literature, including the American College of Physicians[1], the European League Against Rheumatism[2], and the Cochrane Database of Systematic Reviews[3-6].   The algorithm has been…

All TreatGx users now have access to the updated treatment algorithms for Acute Gout and Peripheral Artery Disease. As always, both of these updates include the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, and drug interactions. Acute Gout  This…

All TreatGx users now have access to the updated treatment algorithms for Depression, Heart Failure – Fluid Retention, Chronic Pain – Trigeminal Neuralgia, and Hyperlipidemia.  Depression  In light of its recent approval in Canada and the US, esketamine nasal spray (Spravato) has been added to the Depression Augmentation/Adjunctive therapy options. Highlights include:  Approved by Health Canada for…